Content

Welcome to the CJU website » LOG IN

Details

GnRH antagonists in the treatment of advanced prostate cancer
Can-Med Clinical Research Inc, Victoria, British Columbia, Canada
Apr 2010 (Vol. 17, Issue 2, Pages( 5063 - 5070)
PMID: 20398443

Abstract

Text-Size + 

  • Analogues of the gonadotropin releasing hormone (GnRH) inhibit the hypothalamic-pituitary-gonadal axis. This has provided treatment modalities for advanced and metastatic prostate cancer. The latest group of analogues, the GnRH antagonists, make promising treatments available that avoid the transient surge in testosterone that occurs with the use of GnRH agonists. Such surges may stimulate tumor growth, causing patients to experience new or worsening cancer symptoms and potential serious adverse effects, including increased bone pain, urinary retention, and spinal cord compression and consequently delay the therapeutic benefits of agonist therapy. Degarelix, an antagonist, recently approved in the United States and Europe, achieves faster, more profound and sustained testosterone suppression and with fewer adverse effects when compared with agonists and other antagonists. This review discusses and compares the compounds degarelix, abarelix, and cetrorelix.

Current Issue

June 2019, Vol.26 No.3
canadian journal of urology mobile